Splicing factor 2/alternative splicing factor contributes to extracellular signal‑regulated kinase activation in hepatocellular carcinoma cells

Zhao,Yawei; Zhu,Ting; Zhang,Xueying; Wang,Qingyang; Zhang,Jiyan; Ji,Wenbin; Ma,Yuanfang

doi:10.3892/mmr.2015.3851

Splicing factor 2/alternative splicing factor contributes to extracellular signal‑regulated kinase activation in hepatocellular carcinoma cells

Authors:
- Yawei Zhao
- Ting Zhu
- Xueying Zhang
- Qingyang Wang
- Jiyan Zhang
- Wenbin Ji
- Yuanfang Ma
View Affiliations

Affiliations: Laboratory of Cellular and Molecular Immunology, Henan University, Kaifeng, Henan 475001, P.R. China, Department of Molecular Immunology, Institute of Basic Medical Sciences, Beijing 100850, P.R. China, Department of Hepatobiliary Surgery, The Chinese PLA General Hospital, Beijing 100853, P.R. China
Published online on: May 26, 2015 https://doi.org/10.3892/mmr.2015.3851
Pages: 3890-3894

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The splicing factor is important in cancer development, modulation numerous tumor suppressors and oncogenes, and regulation of multiple signaling pathways. Splicing factor 2/alternative splicing factor (SF2/ASF) is a proto‑oncogene, which has been implicated in the development of hepatocellular carcinoma. However, the underlying molecular mechanism remains to be elucidated. In the present study, it was identified that SF2 knockdown had no effect on tumor necrosis factor (TNF)‑α‑induced activation of the c‑Jun N‑terminal protein kinase (JNK) pathway, the p38 pathway, or the IKK pathway in hepatoma cell lines. However, SF2 knockdown led to reduced levels of basal ERK activation and TNF‑α‑induced ERK activation, without changing the protein levels of ERK. Consequently, SF2 knockdown marginally enhanced TNF‑α‑induced cell death. Furthermore, SF2 knockdown and blockade of ERK activation partially suppressed TNF‑α‑induced interleukin‑6 expression. As SF2 knockdown exhibited no role in basal Akt activation and serum‑induced Akt activation, it is unlikely that SF2 affects ERK activation through modulating the protein levels of certain growth factor receptors. In conclusion, the data suggest that SF2 contributes to the elevated levels of ERK activation in hepatocellular carcinoma cells through modulating key component(s) downstream of growth factor receptors and upstream of ERK.

View Figures

View References

1	Llovet JM, Burroughs A and Bruix J: Hepatocellular carcinoma. Lancet. 362:1907–1917. 2003. View Article : Google Scholar : PubMed/NCBI
2	Worster DT, Schmelzle T, Solimini NL, Lightcap ES, Millard B, Mills GB, Brugge JS and Albeck JG: Akt and ERK control the proliferative response of mammary epithelial cells to the growth factors IGF-1 and EGF through the cell cycle inhibitor p57Kip2. Sci Signal. 5:ra192012. View Article : Google Scholar : PubMed/NCBI
3	Zhang J, Wang Q, Zhu N, Yu M, Shen B, Xiang J and Lin A: Cyclic AMP inhibits JNK activation by CREB-mediated induction of c-FLIP_L and MKP-1, thereby antagonizing UV-induced apoptosis. Cell Death Differ. 15:1654–1662. 2008. View Article : Google Scholar : PubMed/NCBI
4	Yan J, Xiang J, Lin Y, Ma J, Zhang J, Zhang H, Sun J, Danial NN, Liu J and Lin A: Inactivation of BAD by IKK inhibits TNF-induced apoptosis independently of NF-κB activation. Cell. 152:304–315. 2013. View Article : Google Scholar : PubMed/NCBI
5	He G and Karin M: NF-kappaB and STAT3 – key players in liver inflammation and cancer. Cell Res. 21:159–168. 2011. View Article : Google Scholar
6	Naugler WE, Sakurai T, Kim S, et al: Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science. 317:121–124. 2007. View Article : Google Scholar : PubMed/NCBI
7	Balkwill F and Coussens LM: Cancer, an inflammatory link. Nature. 431:405–406. 2004. View Article : Google Scholar : PubMed/NCBI
8	Sakurai T, Itoh K, Higashisuji H, Nonoguchi K, Liu Y, Watanabe H, Nakano T, Fukumoto M, Chiba T and Fujita J: Cirp protects against tumor necrosis factor-α-induced apoptosis via activation of extracellular signal-regulated kinase. BBA-Mol Cell Res. 1763:290–295. 2005.
9	Suarez-Cuervo C, Harris KW, Kallman L, Vaananen HK and Selander KS: Tumor necrosis factor-alpha induces interleukin-6 production via extracellular-regulated kinase 1 activation in breast cancer cells. Breast Cancer Res Treat. 80:71–78. 2003. View Article : Google Scholar : PubMed/NCBI
10	Venables JP: Aberrant and alternative splicing in cancer. Cancer Res. 64:7647–7654. 2004. View Article : Google Scholar : PubMed/NCBI
11	Srebrow A and Kornblihtt AR: The connection between splicing and cancer. J Cell Sci. 119:2635–2641. 2006. View Article : Google Scholar : PubMed/NCBI
12	Kim E, Goren A and Ast G: Insights into the connection between cancer and alternative splicing. Trends Genet. 24:7–10. 2008. View Article : Google Scholar
13	Yoshida K, Sanada M, Shiraishi Y, et al: Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 478:64–69. 2011. View Article : Google Scholar : PubMed/NCBI
14	Quesada V, Ramsay AJ and Lopez-Otin C: Chronic lymphocytic leukemia with SF3B1 mutation. N Engl J Med. 366:25302012. View Article : Google Scholar : PubMed/NCBI
15	Karni R, de Stanchina E, Lowe SW, Sinha R, Mu D and Krainer AR: The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat Struct Mol Biol. 14:185–193. 2007. View Article : Google Scholar : PubMed/NCBI
16	Yea S, Narla G, Zhao X, Garg R, Tal-Kremer S, Hod E, Villanueva A, Loke J, Tarocchi M, Akita K, Shirasawa S, Sasazuki T, Martignetti JA, Llovet JM and Friedman SL: Ras promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma. Gastroenterology. 134:1521–1531. 2008. View Article : Google Scholar : PubMed/NCBI
17	Muñoz Ú, Puche JE, Hannivoort R, Lang UE, Cohen-Naftaly M and Friedman SL: Hepatocyte growth factor enhances alternative splicing of the Kruppel-like factor 6 (KLF6) tumor suppressor to promote growth through SRSF1. Mol Cancer Res. 10:1216–1227. 2012. View Article : Google Scholar : PubMed/NCBI
18	Tang G, Minemoto Y, Dibling B, Purcell NH, Li Z, Karin M and Lin A: Inhibition of JNK activation through NF-κB target genes. Nature. 414:313–317. 2001. View Article : Google Scholar : PubMed/NCBI
19	Anczuków O, Rosenberg AZ, Akerman M, Das S, Zhan L, Karni R, Muthuswamy SK and Krainer AR: The splicing factor SRSF1 regulates apoptosis and proliferation to promote mammary epithelial cell transformation. Nat Struct Mol Biol. 19:220–228. 2012. View Article : Google Scholar : PubMed/NCBI
20	Geuking MB, Cahenzli J, Lawson MA, Ng DC, Slack E, Hapfelmeier S, McCoy KD and Macpherson AJ: Intestinal bacterial colonization induces mutualistic regulatory T cell responses. Immunity. 34:794–806. 2011. View Article : Google Scholar : PubMed/NCBI
21	Panasyuk G, Nemazanyy I, Zhyvoloup A, Filonenko V, Davies D, Robson M, Pedley RB, Waterfield M and Gout I: mTORbeta splicing isoform promotes cell proliferation and tumorigenesis. J Biol Chem. 284:30807–30814. 2009. View Article : Google Scholar : PubMed/NCBI